With the incorporation of cancer immunotherapy into clinical practice, the development of combination therapies, biomarkers, and new cancer immunotherapy-related drugs and devices is being promoted worldwide. However, a large-scale center for cancer immunology was missing in Japan, delaying the development of cancer immunology-related medicine, diagnostics, and devices.
The Center for Cancer Immunotherapy and Immunobiology (CCII) considers collaborative research between academia and pharmaceutical industry necessary for the growth of basic and clinical research, as well as to swiftly deliver its results to patients. To actively promote such research and development, the CCII’s new research building (to be completed FY2022) will be equipped with spaces for companies on each floor. This will facilitate rapid advancement in immunotherapy research in a way that brings together basic, clinical, and corporate researchers, as well as ensures international competitiveness.